Phase 1 clinical trial of LFD-200 in Rheumatoid Arthritis is ongoing; Enrolling and dosing is underway
Developing new therapies for autoimmune and inflammatory disorders using a novel, targeted ADC based delivery platform
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.
-
About Lifordi
Leveraging the success of ADCs in oncology to treat autoimmune and inflammatory disorders
-
Leadership
Experienced business and scientific leadership in drug development, immunology and inflammatory disorders
-
Technology
Our targeted ADC platform has demonstrated superior efficacy and safety in multiple disease models